
US-based biotech firm Biomarin has released its full-year financial report on Wednesday, and in connection with the report came the company’s 2022 sales prognosis for potential cash cow Voxzogo.
Biomarin is projecting that sales of the treatment for achondroplasia, also known as dwarfism, could reach as much as USD 115m in 2022.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app